View More Recent Stories
-
BofA Securities Upgrades Cardinal Health (CAH) to Buy
-
Senator Warren Asks FTC to Probe Cardinal Health-GI Alliance Deal - Bloomberg
-
T2 Biosystems (TTOO) Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
-
Mizuho Starts Cardinal Health (CAH) at Outperform
-
The election implications for healthcare technology and distribution stocks - BofA
-
Cardinal Health (CAH) Tops Q1 EPS by 26c; raises guidance
-
T2 Biosystems (TTOO) Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
-
TD Cowen Reiterates Hold Rating on Cardinal Health (CAH)
-
Cardinal Health (CAH) PT Raised to $140 at Baird
-
Cardinal Health (CAH) to acquire Integrated Oncology Network for $1.115B in cash
-
Cardinal Health (CAH) PT Raised to $125 at Argus
-
Cardinal Health (CAH) expands medical product distribution footprint in Northeast Ohio
-
Cardinal Health (CAH) PT Raised to $119 at Deutsche Bank
-
Cardinal Health (CAH) PT Raised to $116 at TD Cowen
-
Cardinal Health (CAH) PT Raised to $110 at Mizuho
-
Cardinal Health (CAH) PT Raised to $137 at Baird
-
Midday movers: UBS, Kellanova rise; Starbucks slips
-
Cardinal Health (CAH) Tops Q4 EPS by 11c, Beats on Revenue; Offers FY25 EPS Guidance
-
Cardinal Health (CAH) PT Raised to $130 at Baird

